The Cooper Companies, Inc (COO)

Rating: HOLD

HOLD (5-tier) · cyclical compounder · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -13% vs spot
• DCF fair value implies -16% vs spot — but this is terminal-value sensitive (exit-multiple $60 vs Gordon $76, 27% apart), so it carries less weight
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -57% vs spot
• Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At 71.71 (Alpha Vantage close, 2026-06-27) COO trades on roughly 15.4x forward earnings, in line with the medical-device peer median of 15.1x. The market is pricing a mature mid-single-digit grower whose myopia-management and fertility premium has largely been competed away, with residual GLP-1 anxiety attached. The engine broadly agrees. The probability-weighted value of 70.05 sits 2.3% below spot; the capex-bridge DCF of 61.39 is lower still, because actual capital spending ($0.362B in FY2025 per Alpha Vantage cash-flow data) runs nearer 9% of revenue than the 5% archetype assumption. Monte Carlo places only a 36.6% probability on fair value exceeding the current price, and two-thirds of outcome variance is driven by the multiple, not the business. A HOLD follows: no margin of safety, no clear overvaluation. The most damaging risk is the structural scenario, a 20% probability of reimbursement, competitive and GLP-1-driven procedure erosion that lands the stock near 30.82, below the 52-week low of 58.89.

The dashboard below is the whole argument on one page: spot ($72) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear case does not need a recession. CooperVision's growth premium rests on daily silicone-hydrogel share gains and MiSight myopia management; Alcon, Johnson & Johnson and Bausch + Lomb are all adding daily-lens capacity, and private-label pressure in the channel compresses price before it shows in volume. CooperSurgical's fertility franchise faces a quieter threat: clinic volumes are flattening, and any durable improvement in ovulatory health from GLP-1 adoption shrinks the IVF funnel rather than feeding it. Margins then compress just as the capital build peaks; capex near $0.36B a year against a slowing top line leaves the model over-built. On trough earnings near 3.25 a share and a 9.5x multiple, the stock settles near 31, below the 52-week low.

Key Debate

P/E Multiple explains 67% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.38 vs analyst floor +0.00 → delta +0.38 (n=31 mgmt / 27 Q&A; 48th pctile across the S&P book, z -0.1).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 696 articles): avg ticker sentiment +0.20 (bullish 27% / bearish 3%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($31) to a 'Bull — Re-Rate' bull case ($124); the probability-weighted blend (PWEV $70) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $31). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 30.82; probability: 0.2.
• Hospital-Capex / Utilization Recession (17%, $52). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 52.34; probability: 0.17.
• Base — Procedure Volume + Innovation (35%, $73). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 72.7; probability: 0.35.
• Growth — New-Product Cycle / Penetration (20%, $98). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 98.14; probability: 0.2.
• Bull — Re-Rate (8%, $124). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 123.95; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $63 and 36% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (67% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 13x terminal FCF multiple → $60. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.085x) implies $70. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 45% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Devices Tools

This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)

Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $4B + PV(terminal) $10B = EV $14B; + net cash → equity $12B ÷ diluted shares 0.20B = $60/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $76/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 12% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $70; EV/Rev → $42.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 15x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-10-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.7% of revenue; cash conversion (OCF/NI) 212% — cash-backed.

Catalyst Calendar

• 2026-08-26 (~49d) — Quarterly earnings — est. EPS $1.12 (AV EARNINGS_CALENDAR)
• 2026-10-01 (~85d) — MyDay / MiSight myopia-management line extension or new-geography launch (authored)
• 2027-02-15 (~222d) — CooperSurgical fertility investor update / capacity expansion (authored)
• 2027-05-20 (~316d) — New-product-cycle margin update (specialty/toric mix) (authored)

Forecast Track Record

• EPS surprise: beat 75.0% of the last 8 quarters; average surprise -2.6%.

Competitive Moat

Narrow moat. A narrow moat — CooperVision's myopia-management/specialty-lens IP and CooperSurgical's fertility installed base give some stickiness but the premium has largely been competed away, so the DCF terminal multiple has no claim above the med-device peer ~15x; if myopia-management share erodes it should compress toward ~13x.

Moat sources:

• FACT: CooperVision myopia-management (MiSight) regulatory clearances and specialty/toric lens IP create modest switching costs for fitted patients
• FACT: CooperSurgical fertility consumables/devices are embedded in IVF clinic workflows (recurring consumable pull-through)
• INFERENCE: duopoly-adjacent lens market (vs J&J Vision, Alcon, Bausch) limits pricing power — premium already competed away per the thesis
• INFERENCE: no evidence of a widening moat — a mid-single-digit grower trading in line with the med-device peer median

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 14.4× forward EPS, vs the house DCF terminal 13.0×, and a peer median 15.085×. The house DCF sits 16% below spot, so the market is pricing in more than the house case — roughly 1.5pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 16.0× (simple median 15.085×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $59–$90, centre $73 (+1% vs spot); spot sits at the 42th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $124.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (19.0); Op margin ±3pp (17.0); Terminal × ±15% (15.0); Capex intensity ±15% (8.0); WACC ±1pp (6.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 13×, FY+5 revenue $5B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• CooperVision organic revenue growth (constant currency) below 2.0% year-on-year (2 consecutive prints → Mid-Cycle — Procedure & R&D Demand). Midpoint of the base path (6% growth) and the recession path (-2%); two prints below it means the lens franchise is tracking the cyclical-downturn scenario, not mid-cycle.
• Consolidated non-GAAP operating margin below 22.9% (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Midpoint of the base margin (24.3%) and the recession margin (21.5%); sustained prints below it indicate price/mix pressure is structural rather than transitory.
• FY revenue guidance cut below $4.40B (single event → Reimbursement / Funding / Utilization Reset). Guidance stands at $4.5B (W26 reconciliation); a cut through $4.40B removes the mid-single-digit growth assumption underpinning the base scenario and the 15.5x base multiple.
• CooperSurgical fertility revenue growth below 0% year-on-year (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Fertility is the higher-growth pillar of the portfolio; two prints of outright decline is the observable mechanism of the structural scenario (GLP-1 and clinic-volume erosion of the IVF funnel).
• Annual capital expenditure above $0.50B while organic revenue growth runs below 4% (single event → Mid-Cycle — Procedure & R&D Demand). FY2025 capex was $0.362B (AV CASH_FLOW); a print above $0.50B against sub-4% growth marks a value-dilutive capacity over-build and directly worsens the capex-bridge DCF.

Fact / Inference / Speculation

• FACT: Spot $72; 52-week range $59–$90; engine rating HOLD; base-case target $70 (-3%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $65 (-10% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $65 (-10% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.